prikaz prve stranice dokumenta Antiresorptivni lijekovi u liječenju osteoporoze
  Download
PDF 462.89 KB
Professional paper - Review paper
Antiresorptivni lijekovi u liječenju osteoporoze
Reumatizam, 61 (2014), 2; 89-94. urn:nbn:hr:184:331926
Novak, Srđan

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Novak, S. (2014). Antiresorptivni lijekovi u liječenju osteoporoze. Reumatizam, 61. (2), 89-94. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:331926

Novak, Srđan. "Antiresorptivni lijekovi u liječenju osteoporoze." Reumatizam, vol. 61, no. 2, 2014, pp. 89-94. https://urn.nsk.hr/urn:nbn:hr:184:331926

Novak, Srđan. "Antiresorptivni lijekovi u liječenju osteoporoze." Reumatizam 61, no. 2 (2014): 89-94. https://urn.nsk.hr/urn:nbn:hr:184:331926

Novak, S. (2014) 'Antiresorptivni lijekovi u liječenju osteoporoze', Reumatizam, 61(2), pp. 89-94. Available at: https://urn.nsk.hr/urn:nbn:hr:184:331926 (Accessed 13 May 2024)

Novak S. Antiresorptivni lijekovi u liječenju osteoporoze. Reumatizam [Internet]. 2014 [cited 2024 May 13];61(2):89-94. Available at: https://urn.nsk.hr/urn:nbn:hr:184:331926

S. Novak, "Antiresorptivni lijekovi u liječenju osteoporoze", Reumatizam, vol. 61, no. 2, pp. 89-94, 2014. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:331926. [Accessed: 13 May 2024]

Metadata
Title (croatian)Antiresorptivni lijekovi u liječenju osteoporoze
Title (english)Antiresorptive agents in the treatment of osteoporosis
AuthorSrđan Novak
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (croatian)
Cilj medikamentoznog liječenja osteoporoze jest uspostaviti ravnotežu između aktivnosti osteoblasta i osteoklasta te time povećati mineralnu gustoću kosti i posljedično smanjiti rizik prijeloma. Antiresorptivni lijekovi suprimiraju djelovanje osteoklasta te na taj način smanjuju razgradnju kosti. Tu pripadaju bisfosfonati, selektivni modulatori estrogenskih receptora (SERM) te denosumab, dok su hormonsko nadomjesno liječenje i kalcitonin danas uglavnom napušteni. Vežući se za kristale hidroksiapatita na površini kosti bisfosfonati inhibiraju resorpciju kosti te posljedično dovode do smanjenja rizika za vertebralne i nevertebralne prijelome. Denosumab je monoklonsko protutijelo koje sprečavanjem interakcije između RANKL-a i RANK-a inhibira osteoklastogenezu i tako smanjuje resorpciju kosti u kortikalnoj i trabekularnoj kosti te posljedično znatno smanjuje rizik za prijelome.
Abstract (english)
The aim of drug treatment of osteoporosis is the balance between activity of osteoblasts and osteoclasts with augmentation of mineral bone density and decrease of fracture risk. Antiresorptive agents depress osteoclasts and diminish resorption of bone. They include bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, while hormone replacement therapy and calcitonin are mostly abandoned. By binding to hydroxyapatite crystals of bone surface bisphosphonates inhibit the resorption of bone and prevent vertebral and non-vertebral fractures. Denosumab is a monoclonal antibody which by hindering interaction between RANKL and RANK inhibits osteoclastogenesis and diminishes bone resorption in cortical and trabecular bones, thus significantly lessening fracture risk.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeProfessional paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleReumatizam
Numberingvol. 61, no. 2, pp. 89-94
p-ISSN0374-1338
e-ISSN2459-6159
URN:NBNurn:nbn:hr:184:331926
Publication2014
Document URLhttps://hrcak.srce.hr/137904
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-09-23 06:45:59